Dose-response : a publication of International Hormesis Society · 2026
Dosimetric Comparison of Intracavitary Versus Combined Intracavitary-Interstitial Image-Guided Brachytherapy in Locally Advanced Cervical Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xi, Zhao Bo, Yu Guiyong, He Zhuokai, Liu Meilian, Wang Rensheng, Hu Kai
Аннотация
PURPOSE: The present study aimed to compare the dose distributions between conventional three-catheter intracavitary (IC) brachytherapy and combined intracavitary-interstitial (IC/IS) brachytherapy in the management of locally advanced cervical cancer (LACC).
MATERIALS AND METHODS: A retrospective dosimetric analysis was performed using data from 78 patients with cervical cancer who underwent high-dose-rate (HDR) brachytherapy. To evaluate the dosimetric advantages of IC/IS brachytherapy, patients were stratified into two groups: those treated with IC brachytherapy and those treated with IC/IS brachytherapy. Dosimetric parameters between the two groups were compared.
RESULTS: In the IC/IS brachytherapy group, V150 values for the high-risk clinical target volume (HR-CTV) were significantly higher than those in the IC group (p < 0.001). Subsequent comparison of organ-at-risk (OAR) dosimetric parameters revealed that D0.1cc, D1cc, D2cc, D5cc, and D10cc values for the bladder and sigmoid colon were significantly lower in the IC/IS group than in the IC group (all p < 0.05).
CONCLUSIONS: Compared with conventional IC brachytherapy, combined IC/IS brachytherapy provides superior HR-CTV coverage with higher doses while simultaneously reducing radiation exposure to the bladder and sigmoid colon, provided that the D90 dose constraint for the HR-CTV is met.
MATERIALS AND METHODS: A retrospective dosimetric analysis was performed using data from 78 patients with cervical cancer who underwent high-dose-rate (HDR) brachytherapy. To evaluate the dosimetric advantages of IC/IS brachytherapy, patients were stratified into two groups: those treated with IC brachytherapy and those treated with IC/IS brachytherapy. Dosimetric parameters between the two groups were compared.
RESULTS: In the IC/IS brachytherapy group, V150 values for the high-risk clinical target volume (HR-CTV) were significantly higher than those in the IC group (p < 0.001). Subsequent comparison of organ-at-risk (OAR) dosimetric parameters revealed that D0.1cc, D1cc, D2cc, D5cc, and D10cc values for the bladder and sigmoid colon were significantly lower in the IC/IS group than in the IC group (all p < 0.05).
CONCLUSIONS: Compared with conventional IC brachytherapy, combined IC/IS brachytherapy provides superior HR-CTV coverage with higher doses while simultaneously reducing radiation exposure to the bladder and sigmoid colon, provided that the D90 dose constraint for the HR-CTV is met.